Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 2019 Jun 3;129(6):2595. doi: 10.1172/JCI129688

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

Holbrook E Kohrt, Roch Houot, Kipp Weiskopf, Matthew J Goldstein, Ferenc Scheeren, Debra Czerwinski, A Dimitrios Colevas, Wen-Kai Weng, Michael F Clarke, Robert W Carlson, Frank E Stockdale, Joseph A Mollick, Lieping Chen, Ronald Levy
PMCID: PMC6546446  PMID: 31157620

Original citation: J Clin Invest. 2012;122(3):1066–1075. https://doi.org/10.1172/JCI61226

Citation for this retraction: J Clin Invest. 2019;129(6):2595. https://doi.org/10.1172/JCI129688

Stanford University School of Medicine recently notified the JCI of concerns regarding Figure 4, A and C, and indicated that the original source data for these figures could not be located. In accordance with the institutional recommendation, the JCI is retracting this article.

Version 1. 06/03/2019

Print issue publication

Footnotes


Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES